Biotech: Life Science Ventures and Commercialization Briefings
INFO
YOUTUBE2026-05-28eu-startups
The Startup Freezing Humans For Tomorrow - Interview with Dr Emil Kendziorra, CEO of Tomorrow.bio
STANCE
00:00
05:00
10:00
15:00
20:00
25:00
30:00
35:00
40:00
9 intervals • swipe left
The Startup Freezing Humans For Tomorrow - Interview with Dr Emil Kendziorra, CEO of Tomorrow.bio
Dr. Emil Kendziorra transitioned from cancer research to establish Tomorrow.bio, a pioneering cryopreservation company in Europe.
STANCE
STANCE MAP
Proponents of Cryopreservation
- Advocate for cryopreservation as a viable alternative to traditional burial, offering potential for future revival
- Highlight the growing interest and investment in cryopreservation technology, indicating a shift towards acceptance
Skeptics of Cryopreservation
- Question the ethical implications and long-term viability of cryopreservation without guaranteed revival
Neutral / Shared
- Acknowledge the current limitations of cryopreservation technology and the need for clear communication with clients
- Recognize the potential for future advancements in medical science to impact the field of cryopreservation
FULL
00:00–05:00
Dr. Emil Kendziorra transitioned from cancer research to establish Tomorrow.bio, a pioneering cryopreservation company in Europe.
- Dr. Emil Kendziorra shifted from a career in cancer research to establish Tomorrow.bio, a leading cryopreservation company in Europe that focuses on preserving both humans and pets
- Tomorrow.bio addresses the gap in European cryopreservation services, offering a unique position in the market with a transparent pricing model
- Kendziorras transition to cryomedicine reflects his commitment to making advanced preservation technologies more accessible to the public
- The company has successfully secured €5 million in funding, showcasing strong investor confidence in the potential of cryopreservation and medical biostasis
- The discussion reveals the operational and emotional challenges encountered during the preservation of the first 20 human patients and 10 pets, highlighting the need for clear communication regarding the limitations of current technology
FULL
05:00–10:00
Dr. Emil Kendziorra founded Tomorrow.bio to advance cryopreservation and medical biostasis, driven by a lifelong passion for longevity.
- Dr. Emil Kendziorras passion for longevity and innovation drives his mission to help people extend their lives
- His motivation to enter medicine and research is rooted in a personal belief in the value of life, rather than a specific traumatic event
- Kendziorra initially aimed to obtain both an MD and a PhD to bridge the gap between basic and translational science, ultimately leading to the creation of a longevity-focused company
- He considers Tomorrow.bio his lifes work, viewing previous ventures as essential steps toward tackling the complex issue of human mortality
- The establishment of Tomorrow.bio marks a significant transition from traditional medical research to the pioneering field of cryopreservation, which he believes has great potential for future advancements in longevity
FULL
10:00–15:00
Dr. Emil Kendziorra founded Tomorrow.bio to advance cryopreservation and medical biostasis, viewing it as a significant solution for extending human life.
- Dr. Emil Kendziorra views cryopreservation as a complex yet impactful solution for extending human life, stemming from his extensive background in biological research
- His entrepreneurial journey through various startups culminated in the founding of Tomorrow.bio, which he regards as his lifes work due to its potential to advance longevity
- Kendziorra emphasizes the financial viability of cryopreservation, positioning it as both a mission-driven initiative and a promising business opportunity
- He acknowledges the current limitations of cryopreservation technology, particularly the challenges surrounding the gap between preservation and potential revival, and stresses the need for transparent communication with patients
- Tomorrow.bio has successfully cryopreserved over 20 human patients and 10 pets, providing critical operational and emotional insights that shape their practices
FULL
15:00–20:00
Tomorrow.bio is a pioneering cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.
- Cryopreservation offers a viable alternative for individuals with terminal illnesses, allowing them to choose preservation over traditional burial or cremation, with the hope of future medical advancements
- Tomorrow.bios business model is based on a growing membership, with over 1,000 individuals enrolled for cryopreservation, each costing approximately €200,000, indicating substantial revenue potential
- The company is structured to provide long-term care for preserved individuals through a nonprofit foundation, which serves as a legal guardian, thereby mitigating financial risks associated with preservation
- Success is measured in three stages: financial viability through membership growth, successful preservation in animals as a precursor to human trials, and the eventual revival of preserved individuals, which may take decades
- Investors in Tomorrow.bio typically have a long-term investment perspective, including family offices and ultra-high-net-worth individuals, reflecting the unique nature of the cryopreservation market
METRICS
REVENUE
200,000 eurosEUR
details
CONTEXT: cost per cryopreservation
WHY: This indicates substantial revenue potential for the company
EVIDENCE: each cryo preservation is 200,000 euros
FULL
20:00–25:00
Tomorrow.bio is a pioneering cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.
- Cryopreservation does not currently ensure revival, as it depends on future technological advancements, making it a riskier alternative to traditional burial or cremation
- Dr. Kendziorra notes that while cryopreservation may offer a better chance of revival than cremation, the exact probabilities remain uncertain and hinge on future medical developments
- The high cost of cryopreservation is attributed to limited demand and the need for specialized medical teams, but economies of scale could significantly lower prices as adoption increases
- Tomorrow.bio plans to enhance accessibility by reducing cryopreservation costs to approximately €25,000 as the technology becomes more mainstream
- The introduction of brain-only preservation provides a more affordable option, although whole-body preservation is still recommended for optimal outcomes
FULL
25:00–30:00
Tomorrow.bio is a pioneering cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.
- The cost of cryopreservation is expected to decrease significantly as participation increases, benefiting from economies of scale in storage and operations
- Many clients currently finance cryopreservation through life insurance policies, alleviating the burden of upfront costs
- Brain-only cryopreservation is offered as a more affordable alternative to whole-body preservation, while still aiming to maintain the individuals identity and consciousness
- Future technological advancements, such as 3D printing of body parts, could potentially enable revival after long-term cryopreservation, although this is not expected in the near term
- The creation of a European cryopreservation organization was motivated by the need for improved medical response capabilities, which were insufficient in existing American services
FULL
30:00–35:00
Tomorrow.bio is a rapidly growing cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.
- Dr. Emil Kendziorra highlights Tomorrow.bios rapid growth, claiming it is 20 times faster than legacy organizations, and emphasizes improvements in cryopreservation quality and accessibility
- He stresses the importance of market education over competition, noting that Tomorrow.bio currently faces no direct competitors in Europe, allowing the company to focus on informing potential clients about cryopreservation benefits
- Kendziorra addresses the shift in perception of cryopreservation from a fringe concept to a legitimate option for terminally ill patients, often considered only after other medical treatments have failed
- He discusses the financial aspects of cryopreservation, indicating that life insurance policies can help manage costs, making the service more accessible for interested individuals
- The conversation includes the potential impact of future technologies, such as 3D printing of organs, which could improve the chances of reviving individuals who have undergone cryopreservation
FULL
35:00–40:00
Tomorrow.bio is a rapidly growing cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.
- Dr. Emil Kendziorra stresses the importance of increasing the number of companies in the cryopreservation sector to improve market education and establish credibility for the technology
- He notes the initial focus on human cryopreservation at Tomorrow.bio, which later expanded to include pets, reflecting a rising interest in preserving animals
- Kendziorra shares his personal commitment to cryopreservation, indicating that he would choose this option over traditional burial or cremation if faced with a terminal illness
- The lack of competition in Europe positions Tomorrow.bio as a leader in cryopreservation, emphasizing quality and accessibility in their services
- He discusses potential innovations in related fields, such as organ bio-banking and cell preservation, highlighting a mission-driven approach to broaden the applications of cryopreservation technology
FULL
40:00–45:00
Tomorrow.bio is a rapidly growing cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.
- Dr. Emil Kendziorra highlights the importance of effective communication to enhance public awareness and acceptance of cryopreservation, noting that approximately 20% of individuals in Europe and the US show interest in this option
- He believes that reaching a milestone of 100,000 sign-ups would necessitate demonstrating the effectiveness of cryopreservation through research, potentially creating a cycle of increased interest and investment
- Kendziorra suggests that endorsements from celebrities and influential figures could help legitimize cryopreservation, making it more attractive to the public and fostering broader acceptance
- He argues that the decision between cryopreservation and traditional burial or cremation should be straightforward, as cryopreservation offers the potential for future revival, presenting a compelling alternative for those with terminal conditions
INFO
YOUTUBE2026-05-06startup grind
HealthTech, BioTech + Wellness VC Panel
STANCE
00:00
05:00
10:00
15:00
20:00
5 intervals • swipe left
HealthTech, BioTech + Wellness VC Panel
The panelists discuss the shift in healthcare towards continuous and preventive care, driven by AI and wearable technology. They express skepticism about the current hype surrounding AI in healthcare, emphasizing the nee…
STANCE
STANCE MAP
Proponents of AI in Healthcare
- Highlight the potential of AI to enhance operational efficiency and reduce administrative burdens
- Emphasize the importance of continuous and preventive care driven by AI advancements
Skeptics of AI Hype
- Caution against over-reliance on AI, stressing the need for human oversight in healthcare
- Express concerns about the implications of AI on medical billing and provider revenue
Neutral / Shared
- Acknowledge the evolving investment landscape towards rational capital allocation
- Recognize the importance of demonstrating product-market fit and operational efficiency in startups
FULL
00:00–05:00
The panelists discuss the shift in healthcare towards continuous and preventive care, driven by AI and wearable technology. They express skepticism about the current hype surrounding AI in healthcare, emphasizing the need for realistic expectations regarding timelines and outcomes.
- Panelists discuss the transition in healthcare towards continuous and preventive care, influenced by AI advancements and the proliferation of wearables and diagnostic tools
- Ari Wright emphasizes the need for longitudinal biological data collection and biosensor development to enhance consumer trust and deliver personalized health recommendations
- Harrison Lieberfarb introduces the Jevons Paradox, suggesting that while AI may optimize healthcare workflows, it could paradoxically increase service demand rather than decrease the need for providers
- The panelists express skepticism about the current hype surrounding AI in healthcare, pointing out that real progress in timelines, costs, and outcomes often falls short of expectations
- There is a shared belief in the potential for innovation in ongoing healthcare management and early detection of health issues
FULL
05:00–10:00
The panelists discuss the integration of AI in healthcare, highlighting its potential to enhance operational efficiency while acknowledging the industry's reliance on traditional processes. They express concerns about the implications of AI on medical billing practices and revenue generation for providers.
- AI is enhancing operational efficiency in healthcare by minimizing the time providers spend on administrative tasks, resulting in measurable benefits
- While AI is establishing a foundational infrastructure in drug development, the industry still heavily relies on traditional physical processes
- The integration of AI in healthcare raises concerns regarding billing practices, as many medical billing codes are time-based, which could lead to decreased revenue for providers if AI shortens patient visit durations
- The future of healthcare may transition towards value-based care models, which could better align with the changes introduced by AI technologies
FULL
10:00–15:00
The panelists discuss the challenges and evolving landscape of AI integration in healthcare, emphasizing the need for diverse revenue streams and operational efficiency. They highlight a shift towards rational capital allocation and measurable outcomes in healthcare investments.
- The panelists address the challenges of integrating AI in healthcare, particularly its effects on medical billing and provider revenue as patient encounter times decrease
- Harrison Lieberfarb points out that startups relying on a single billing code struggle to attract investment, highlighting the need for diverse revenue streams and operational efficiency
- Rainy Guo observes that current healthcare investment valuations are significantly lower than their peak, indicating a shift towards rational capital allocation and a focus on quality companies
- Guo emphasizes the necessity of incorporating new technologies into existing healthcare workflows without disruption, and calls for clear, accountable outcomes from innovations
- The panelists concur that the investment landscape is evolving towards a pragmatic approach, prioritizing measurable results and sustainable growth over speculative opportunities
METRICS
VALUATION
almost a 50% of what it was compared to the highest point%
details
CONTEXT: current healthcare investment valuations
WHY: This indicates a significant correction in the market, suggesting a more cautious investment approach
EVIDENCE: the valuation if we think about is still like almost a 50% of what it was compared to the the highest point
OTHER
30% of the time doctors spend on operational administration matters a day%
details
CONTEXT: potential efficiency gains from AI integration
WHY: This highlights the potential for AI to significantly reduce administrative burdens in healthcare
EVIDENCE: this company reduced whatever 30% of the time doctors spend an operational administration matters a day
FULL
15:00–20:00
The panelists discuss the current investment climate in healthcare, emphasizing the importance of demonstrating product-market fit and the need for substantial annual recurring revenue before securing funding. They express concerns about the over-reliance on AI as a selling point without clear operational outcomes.
- Investors are prioritizing founders who can clearly articulate a vision for building substantial healthcare and med tech businesses, with market size being a crucial consideration
- Many early-stage healthcare companies remain pre-revenue, yet investors are looking for signs of product-market fit and validation of commercial viability before making commitments
- The current investment climate has heightened expectations for traction, with Series A funding typically requiring at least $2 million in annual recurring revenue, often targeting $3 to $4 million
- While AI is a prominent trend, investors warn against companies that rely heavily on AI as a selling point without providing clear outcomes and operational efficiencies
- Healthcare valuations are currently more favorable than in other sectors, presenting strategic opportunities, particularly for companies focused on administrative and operational enhancements
FULL
20:00–25:00
The panelists discussed the importance of persistence in securing funding, emphasizing that founders should connect with around 200 investors. They highlighted the need for effective use of AI tools in business strategies while cautioning against relying solely on AI as a selling point.
- Founders should connect with approximately 200 investors and demonstrate persistence, as determination plays a crucial role in securing funding
- The investment landscape currently highlights the need for agency and effective use of AI tools in business strategies
- While AI is an important factor, it should not be the primary selling point; companies must also demonstrate tangible outcomes and operational improvements
- Investors are particularly interested in healthcare companies with reasonable valuations, especially in contrast to the inflated valuations seen in AI software infrastructure
- The panelists expressed enthusiasm for upcoming pitches, reflecting a proactive stance in seeking out promising investment opportunities
METRICS
OTHER
200investors
details
CONTEXT: of investors founders should connect with
WHY: Connecting with a larger number of investors increases the chances of securing funding
EVIDENCE: you should be planning to talk to 200 investors
INFO
YOUTUBE2026-04-30sifted
Hertility CEO, Helen O’Neill on building a foundational model for women's health
STANCE
00:00
05:00
10:00
15:00
20:00
25:00
30:00
7 intervals • swipe left
Hertility CEO, Helen O’Neill on building a foundational model for women's health
Hertility, founded by Helen O'Neill, addresses the significant gap in women's health care, particularly in gynecological diagnostics. The startup has raised over $29 million and completed more than 700,000 health assessm…
STANCE
STANCE MAP
Proponents of Women's Health Innovation
- Highlight the urgent need for improved womens health care and faster diagnosis
- Emphasize the importance of integrating innovative technologies in healthcare systems
Critics of Current Healthcare Models
- Point out the systemic barriers and biases in funding and research for womens health
- Question the inclusivity and generalizability of health solutions developed from a predominantly wealthier demographic
Neutral / Shared
- Acknowledge the logistical challenges in conducting clinical trials involving women
- Recognize the growing awareness among investors about the importance of womens health
FULL
00:00–05:00
Hertility, founded by Helen O'Neill, addresses the significant gap in women's health care, particularly in gynecological diagnostics. The startup has raised over $29 million and completed more than 700,000 health assessments, aiming to reduce the average diagnosis time for conditions like endometriosis.
- Helen ONeill, CEO of Hertility, stresses the urgency for improved womens health care, expressing frustration over the gap between knowledge and actionable solutions
- Hertility originated as a clinical trial focused on creating predictive diagnostic algorithms for gynecological conditions, aiming to reduce the average diagnosis time of up to nine years for common womens health issues
- The startup has successfully raised over $29 million and conducted more than 700,000 health assessments, demonstrating its significant influence on womens health diagnostics
- ONeill highlights the historical neglect of womens health in research, where male bodies have often been the standard, resulting in fewer accessible fertility tests for women
- The variability of womens hormones complicates the diagnosis and treatment of health conditions, underscoring the need for a customized approach to womens health care
FULL
05:00–10:00
Hertility is addressing the significant gap in women's health care by developing a diagnostic testing system that supports women through their fertility journeys. The company aims to reduce the lengthy diagnosis time for conditions like endometriosis by leveraging a multimodal data set for accurate diagnosis.
- Hertility CEO Helen ONeill emphasizes the logistical hurdles in including women in clinical trials, particularly the challenges of gathering reliable data during specific phases of the menstrual cycle
- The underrepresentation of women in clinical trials has resulted in significant knowledge gaps, with 80% of drugs withdrawn due to adverse reactions in women, highlighting the urgent need for more inclusive research
- Hertility has created a comprehensive health assessment system that prioritizes women based on suspected conditions, followed by remote blood testing to expedite diagnoses, aiming to address the lengthy average wait for conditions like endometriosis
- The company is developing a multimodal data set that integrates health assessments, blood results, and ultrasound images, which will be utilized to train AI models for accurate diagnosis of womens health issues
- ONeill envisions leveraging this extensive data set to establish foundational models for diagnosing and treating womens health conditions, with potential collaborations with healthcare systems or the development of proprietary Hertility products
METRICS
OTHER
80% of drugs withdrawn due to adverse reactions in women%
details
CONTEXT: percentage of drugs withdrawn related to women's health
WHY: This statistic underscores the critical need for inclusive research to ensure women's safety
EVIDENCE: if you think that eight out of 10 drugs that were taken off the market were to do with adverse reactions in women
FULL
10:00–15:00
Hertility has developed a diagnostic testing system that significantly reduces the diagnosis time for conditions like endometriosis. The company utilizes a multimodal data strategy to enhance the understanding of women's health issues.
- Hertility has established a health assessment and diagnostic testing system that enables rapid diagnoses for conditions like endometriosis, achieving 98-99% confidence in just eight days, compared to an average of nine years through traditional NHS methods
- The company employs a multimodal data strategy, integrating health assessments, blood results, and ultrasound images to create a comprehensive dataset that enhances the understanding and diagnosis of womens health issues
- Hertilitys Gain AI system automates clinical workflows, including blood interpretation and ultrasonography, improving healthcare efficiency and allowing providers to concentrate more on patient care
- Concerns have been raised regarding the demographic representation of the data collected, as it predominantly reflects wealthier women, which may impact the inclusivity of the health solutions being developed
- The backlog in gynecological care, worsened by the COVID-19 pandemic, underscores the pressing need for innovative solutions, with over 700,000 women in the UK currently awaiting appointments
METRICS
OTHER
over 700,000units
details
CONTEXT: of women waiting for gynecological care in the UK
WHY: This backlog highlights the urgent need for innovative healthcare solutions
EVIDENCE: there are over 700,000 women on a wait list to see a gynecologist in the UK
FULL
15:00–20:00
Hertility is addressing the significant gap in women's health care by developing a diagnostic testing system that supports women through their fertility journeys. The company aims to reduce the lengthy diagnosis time for conditions like endometriosis by leveraging a multimodal data set for accurate diagnosis.
- Hertilitys user base includes 25% of individuals aged 18 to 25, reflecting a demographic diversity that challenges the notion that only wealthier women seek their services
- The company offers flexible payment options to enhance accessibility, recognizing that health often takes a backseat until urgent needs arise, similar to consumer electronics
- Hertility has completed 29 clinical trials to validate its at-home testing methods, addressing clinician skepticism about their reliability compared to traditional blood tests
- Capillary blood testing, which uses less invasive finger pricks, is promoted as a safer alternative to venipuncture, especially for women who may be anemic or averse to needles
- Helen ONeill emphasizes the importance of integrating Hertilitys model into national health systems to potentially reduce diagnosis times and unnecessary surgeries, aligning with new womens health initiatives
METRICS
OTHER
25%%
details
CONTEXT: percentage of users aged 18 to 25
WHY: This reflects a demographic diversity that challenges stereotypes about their user base
EVIDENCE: 25% of that database are 18 to 25-year-olds
FULL
20:00–25:00
Hertility is developing a diagnostic testing system to improve women's health care, particularly in diagnosing conditions like endometriosis. The company aims to scale its model globally while addressing the challenges of operating in a healthcare system that typically offers free services.
- Hertility operates in a challenging UK healthcare environment characterized by resistance to paying for services, which has led to low pricing for their tests
- The company has successfully navigated regulatory challenges and aims to scale its model globally, drawing on its experience in a system that typically offers free healthcare
- Currently, Hertility charges £249 for a full health assessment, which includes a clinician consultation, positioning it as a cost-effective alternative to multiple traditional appointments
- While direct-to-consumer sales remain the primary revenue stream, Hertility plans to introduce software licensing as a medical device in the US and Australia within the next year, pending FDA approval
- Despite difficulties in securing funding for what is seen as a niche market, Hertility has established multiple revenue streams that bolster its growth and resilience in the current economic landscape
METRICS
OTHER
£249GBP
details
CONTEXT: cost of a full health assessment
WHY: This positions Hertility as a cost-effective alternative to multiple traditional appointments
EVIDENCE: we now include a um a call with one of our clinicians so it's 249 pounds
FULL
25:00–30:00
Hertility has developed a diagnostic testing system that can diagnose endometriosis with 98-99% confidence in eight days, significantly reducing the average nine-year wait. The company aims to improve women's health care by addressing logistical challenges and enhancing patient management systems.
- Hertility aims to significantly reduce the diagnosis time for conditions like endometriosis, achieving results in eight days compared to the typical nine-year wait in the UK
- The company is creating a modular patient management system designed to improve efficiency and lower costs for healthcare providers, particularly in the US market
- Hertilitys tiered approach to health assessments and blood tests addresses the logistical challenges associated with womens health diagnosis and treatment
- There is a notable contrast in the adoption of new technologies between the US and the UK, with the US showing greater enthusiasm despite the UKs loyalty to its NHS
- User testimonials indicate that Hertilitys services lead to faster diagnoses and treatments compared to traditional healthcare pathways
METRICS
OTHER
16 billionGBP
details
CONTEXT: cost to the UK government for undiagnosed endometriosis
WHY: This financial burden underscores the need for more efficient diagnostic solutions
EVIDENCE: it costs the UK government 16 billion annually
FULL
30:00–35:00
Hertility is addressing the gender disparity in healthcare by developing a diagnostic testing system for women's health, particularly in diagnosing endometriosis. The company aims to leverage existing opportunities in the U.S.
- Helen ONeill points out the gender disparity in venture capital, where investment decisions are often made by all-male boards, limiting opportunities for innovations in womens health
- She argues that the potential market for womens health, which includes menopause, fertility, and cardiovascular health, is significantly underestimated and much larger than the commonly referenced trillion-dollar opportunity
- ONeill highlights the ongoing need for funding to leverage existing opportunities, especially in the U.S. market, where there is a strong interest in transformative health technologies
- The discussion indicates a growing awareness among investors about the importance of womens health, although challenges persist in altering established perceptions
Loading more...